logo-loader
viewFresenius Medical Care

Fresenius Medical Care pays €485 million for Euromedic’s Dialysis Business

euro_dollar_cubes_350_4d235c3a4a1df.jpg

Fresenius Medical Care (NYSE: FMS) said Tuesday it has bought Euromedic International's dialysis business for EUR485 million. 


International Dialysis Centers, as the unit is called, operates a total of 70 clinics in nine countries.  It currently treats over 8,200 dialysis patients mainly in Central and Eastern Europe, an area Fresenius Medical Care sees as a key component to its overall growth strategy. 


Fresenius Medical Care already operates 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa.


Fresenius Medical Care said it will use its cash flow and borrowing capacity to finance the acquisition, which is expected to add $180 million in annual revenue and be accretive to Fresenius Medical Care’s earnings in the first year after closing. 


Based in Budapest, Hungary, Euromedic International owns and operates 140 medical centers across Eastern Europe.  Among its owners are private equity firms Ares Life Sciences, Montagu Private Equity, and Merrill Lynch Global Private Equity, the private equity arm of Merrill Lynch.   


The deal, subject to regulatory approvals, is expected to close in the first half of 2011.

Quick facts: Fresenius Medical Care

Price: 37.13 USD

NYSE:FMS
Market: NYSE
Market Cap: $22.3 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn reveals its drug inhibits colon carcinoma metastases...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive its flagship drug leronlimab inhibited a human colon carcinoma cell line metastases to liver and lung in a well-accepted mouse model. Pourhassan says the company plans to file an IND for expanded access for a Phase 2 basket...

10 hours, 40 minutes ago

2 min read